Literature DB >> 2423808

Indoramin in the hypertensive patient with concomitant disease: clinical experience.

C Rosendorff.   

Abstract

Hypertension has a high prevalence in most countries, so it is to be expected that hypertension will be found together with other common diseases in many patients. The association between the hypertension and the concomitant disease may be causal or casual. The presence of some other disease in the hypertensive patient often places severe restraints on the choice of antihypertensive therapy. Indoramin, an alpha adrenoreceptor antagonist may be used without ill-effect in the therapy of hypertension in patients who also have chronic obstructive airways disease, congestive heart failure, mild renal failure, peripheral vascular disease, angina pectoris, and diabetes mellitus. In at least some of these patients, the use of beta adrenoreceptor blocking drugs or thiazide diuretics would be contraindicated. We do not know whether these advantages of indoramin are unique or whether they are a general property of all alpha-adrenoreceptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423808     DOI: 10.1097/00005344-198600082-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways.

Authors:  Marina Cruz-Lozano; Adrián González-González; Juan A Marchal; Esperanza Muñoz-Muela; Maria P Molina; Francisca E Cara; Anthony M Brown; Gerardo García-Rivas; Carmen Hernández-Brenes; Jose A Lorente; Pedro Sanchez-Rovira; Jenny C Chang; Sergio Granados-Principal
Journal:  Eur J Nutr       Date:  2018-11-21       Impact factor: 5.614

2.  Orthotopic Transplantation of Mouse Mammary Epithelial Cells.

Authors:  Marisa M Faraldo; Marina A Glukhova; Marie-Ange Deugnier
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.